Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company, announced on August 2, 2024, that it granted stock options and restricted stock units to a newly hired employee on August 1. The grants include:
1. Non-statutory stock options to purchase 13,000 ordinary shares
2. Restricted stock units for 7,000 ordinary shares
These grants were made under the company's 2024 Inducement Stock Option and Incentive Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $3.48 per share, equal to the closing price on August 1, 2024. They have a ten-year term and vest over four years. The restricted stock units also vest over four years, with 25% vesting annually.
Mural Oncology plc (Nasdaq: MURA), un'azienda di oncologia immunitaria in fase clinica, ha annunciato il 2 agosto 2024 di aver concesso opzioni su azioni e unità di azioni riservate a un nuovo dipendente il 1° agosto. Le concessioni includono:
1. Opzioni su azioni non statutarie per l'acquisto di 13.000 azioni ordinarie
2. Unità di azioni riservate per 7.000 azioni ordinarie
Queste concessioni sono state effettuate nell'ambito del Piano di Opzioni Azionarie di Induzione e Incentivi 2024 della società, in conformità con la Regola 5635(c)(4) della quotazione Nasdaq. Le opzioni hanno un prezzo d'esercizio di $3,48 per azione, equivalente al prezzo di chiusura del 1° agosto 2024. Hanno una durata di dieci anni e si maturano in quattro anni. Anche le unità di azioni riservate si maturano nel corso di quattro anni, con il 25% che si matura annualmente.
Mural Oncology plc (Nasdaq: MURA), una empresa de inmuno-oncología en etapa clínica, anunció el 2 de agosto de 2024 que otorgó opciones sobre acciones y unidades de acciones restringidas a un nuevo empleado el 1 de agosto. Las concesiones incluyen:
1. Opciones de acciones no estatutarias para la compra de 13,000 acciones ordinarias
2. Unidades de acciones restringidas para 7,000 acciones ordinarias
Estas concesiones se realizaron bajo el Plan de Opciones de Acciones de Inducción e Incentivos 2024 de la compañía, de acuerdo con la Regla de Cotización 5635(c)(4) de Nasdaq. Las opciones tienen un precio de ejercicio de $3.48 por acción, igual al precio de cierre del 1 de agosto de 2024. Tienen un término de diez años y se consolidan durante cuatro años. Las unidades de acciones restringidas también se consolidan durante cuatro años, con un 25% consolidándose anualmente.
Mural Oncology plc (Nasdaq: MURA), 임상 단계 면역종양학 회사는 2024년 8월 2일 새로운 직원에게 8월 1일에 주식 옵션과 제한 주식 단위를 부여했다고 발표했습니다. 부여 내용은 다음과 같습니다:
1. 13,000주 보통주의 비법정 주식 옵션
2. 7,000주 보통주에 대한 제한 주식 단위
이 부여는 회사의 2024년 유도 주식 옵션 및 인센티브 계획에 따라 이루어졌으며, Nasdaq 상장 규칙 5635(c)(4)에 따라 진행되었습니다. 주식 옵션의 행사 가격은 주당 $3.48으로, 2024년 8월 1일의 종가와 동일합니다. 옵션의 유효 기간은 10년이며, 4년에 걸쳐 취득됩니다. 제한 주식 단위 또한 4년에 걸쳐 취득되며, 매년 25%씩 취득됩니다.
Mural Oncology plc (Nasdaq: MURA), une entreprise d'immuno-oncologie en phase clinique, a annoncé le 2 août 2024 qu'elle avait accordé des options d'achat d'actions et des unités d'actions restreintes à un nouvel employé le 1er août. Les concessions comprennent :
1. Options d'actions non statutaires pour l'achat de 13 000 actions ordinaires
2. Unités d'actions restreintes pour 7 000 actions ordinaires
Ces concessions ont été effectuées dans le cadre du Plan d'Options d'Achat d'Actions et d'Incitations de 2024 de la société, conformément à la Règle de Cotation 5635(c)(4) de Nasdaq. Les options d'achat d'actions ont un prix d'exercice de 3,48 $ par action, égal au prix de clôture du 1er août 2024. Elles ont une durée de dix ans et acquis 4 ans. Les unités d'actions restreintes acquièrent également sur une période de quatre ans, avec 25% qui acquièrent chaque année.
Mural Oncology plc (Nasdaq: MURA), ein biopharmazeutisches Unternehmen in klinischer Phase der Immunonkologie, gab am 2. August 2024 bekannt, dass es einem neu eingestellten Mitarbeiter am 1. August Aktienoptionen und eingeschränkte Aktieneinheiten gewährt hat. Die Gewährungen umfassen:
1. Nicht-statutäre Aktienoptionen zum Erwerb von 13.000 Stammaktien
2. Eingeschränkte Aktieneinheiten für 7.000 Stammaktien
Diese Gewährungen erfolgten im Rahmen des Mitarbeiteraktienoptions- und Anreizplans 2024 des Unternehmens, gemäß der Nasdaq-Listing-Regel 5635(c)(4). Die Aktienoptionen haben einen Ausübungspreis von 3,48 USD pro Aktie, was dem Schlusskurs vom 1. August 2024 entspricht. Sie haben eine Laufzeit von zehn Jahren und werden über vier Jahre vests. Die eingeschränkten Aktieneinheiten vests ebenfalls über vier Jahre, mit 25 % jährlich.
- Mural Oncology is attracting new talent with equity-based compensation
- The company has an established inducement plan for new hires, indicating a structured approach to recruitment
- None.
WALTHAM, Mass. and DUBLIN, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced that on August 1, the Company granted to one newly hired employee (i) non-statutory stock options to purchase an aggregate of 13,000 ordinary shares of the Company and (ii) restricted stock units with respect to an aggregate of 7,000 ordinary shares of the Company, pursuant to the Company’s 2024 Inducement Stock Option and Incentive Plan, each as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price of
About Mural Oncology
Mural Oncology is leveraging its novel protein engineering platform to develop cytokine-based immunotherapies for the treatment of cancer. By combining our expertise in cytokine biology and immune cell modulation and our protein engineering platform, we are developing medicines to deliver meaningful and clinical benefits to people living with cancer. Our mission is to broaden the potential and reach of cytokine-based immunotherapies to improve the lives of patients. Our lead candidate, nemvaleukin, is currently in potentially registrational trials in mucosal melanoma and platinum-resistant ovarian cancer. Mural Oncology has its registered office in Dublin, Ireland, and its primary facilities in Waltham, Mass. For more information, visit Mural Oncology’s website at www.muraloncology.com and follow us on LinkedIn and X.
Contact
Katie Sullivan
katie.sullivan@muraloncology.com
FAQ
What stock options did Mural Oncology (MURA) grant to a new employee on August 1, 2024?
How many restricted stock units did Mural Oncology (MURA) award to the new hire on August 1, 2024?
What is the vesting schedule for the stock options granted by Mural Oncology (MURA) on August 1, 2024?
Under which plan did Mural Oncology (MURA) grant the inducement awards on August 1, 2024?
